Induction of de novo HCV core-specific cell-;mediated immune responses and enhancement of neutralizing antibodies response by CIGB-230, a DNA-based vaccine candidate, on triple therapy with IFN-and#945; plus ribavirin
vaccine candidate based on the mixture of a DNA plasmid, expressing HCV structural proteins, with recombinant HCV core protein. In this work CIGB-230 was administered in different schedules regarding ... plus ribavirin…

